drugset / Trial / NCT04167553
Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities
RandomizedParallel-groupDouble-blindTreatment
Summary
The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
Timeline
- Start
- 2019-08-30
- Primary completion
- 2020-12-09
- Completion
- 2020-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efpegerglucagon | Protein / enzyme biologic | 0.02 mg/kg | — |
| Subject | Efpegerglucagon | Protein / enzyme biologic | 0.04 mg/kg | — |
| Subject | Efpegerglucagon | Protein / enzyme biologic | 0.06 mg/kg | — |